Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.

Hennessy, Brian; Zierhut, Matthew L; Kracker, Hilke; Keenan, Alexander; Sidorenko, Tatiana

Hennessy, Brian; Zierhut, Matthew L; Kracker, Hilke; Keenan, Alexander; Sidorenko, Tatiana.

Afiliación

Hennessy B; Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland. Electronic address: bhennes4@its.jnj.com.
Zierhut ML; Certara, Inc, San Diego, CA, USA.
Kracker H; Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland.
Keenan A; Janssen Research & Development, LLC, Spring House, USA.
Sidorenko T; Actelion Pharmaceuticals Ltd, Part of Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland.

Mult Scler Relat Disord ; 64: 103908, 2022 Aug.

Article en En | MEDLINE | ID: mdl-35803162

Asunto(s)

Esclerosis Múltiple Recurrente-Remitente; Esclerosis Múltiple; Acetato de Glatiramer/uso terapéutico; Humanos; Interferon beta-1b/uso terapéutico; Esclerosis Múltiple/tratamiento farmacológico; Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico; Recurrencia; Adulto Joven

Palabras clave

(Confirmed) disability accumulation; Annualized relapse rate; Disease-modifying therapies; Model-based meta-analysis; Ponesimod; Relapsing multiple sclerosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Límite: Adult / Humans Idioma: En Revista: Mult Scler Relat Disord Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google